WEKO3
アイテム
{"_buckets": {"deposit": "6629e0fb-2b6b-4c26-8695-7e1975732714"}, "_deposit": {"created_by": 2, "id": "1088", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1088"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001088", "sets": ["11"]}, "author_link": ["5220", "5223", "5222", "5231", "5234", "5228", "5225", "5230", "5232", "5219", "5226", "5227", "5229", "5221", "5224", "5218", "5233"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "E239", "bibliographicPageStart": "E232", "bibliographicVolumeNumber": "48", "bibliographic_titles": [{"bibliographic_title": "Hepatology Research"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Aim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs. Methods: A total of 107 patients with chronic HCV infection were treated with DAAs. Daclatasvir/asunaprevir or sofosbuvir/ledipasvir was used for HCV 1B infection, and sofosbuvir/ribavirin for HCV 2A/2B infection. The PROs measured at the start of treatment and 1 year after the start of treatment were cirrhosis-related symptom score (CSS), presence of restless legs syndrome (RLS), Epworth sleepiness scale (ESS), Pittsburg sleep quality index (PSQI), Kessler 6 score (K-6), and the SF-36 to measure quality of life (QOL). All patients had a sustained virologic response rate of 24. Results: The CSS, PSQI, K-6, and RLS scores were improved 1 year after beginning treatment. However, QOL had not recovered. Changes in total CSS were correlated with HCV genotype, sex, hypertensive drug use, serum low-density lipoprotein, and ESS at the start of treatment and RLS 1 year after the start of treatment. The factors that contributed to worsening of CSS were HCV genotype 2B and RLS 1 year after the start of treatment. Conclusion: Treatment with DAAs eliminated HCV-RNA and improved most symptoms, but QOL did not recover.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Hepatology Research, 48(3), pp.E232-E239; 2018", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本肝臓学会"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/hepr.12974", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2017 The Japan Society of Hepatology. This is the peer reviewed version of the following article: Hepatology Research, 48(3), pp.E232-E239; 2018, which has been published in final form at http://dx.doi.org/10.1111/hepr.12974. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "13866346", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "The Japan Society of Hepatology"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ichikawa, Tatsuki"}], "nameIdentifiers": [{"nameIdentifier": "5218", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyaaki, Hisamitsu"}], "nameIdentifiers": [{"nameIdentifier": "5219", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miuma, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "5220", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taura, Naota"}], "nameIdentifiers": [{"nameIdentifier": "5221", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motoyoshi, Yasuhide"}], "nameIdentifiers": [{"nameIdentifier": "5222", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akahoshi, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "5223", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Satomi"}], "nameIdentifiers": [{"nameIdentifier": "5224", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Junpei"}], "nameIdentifiers": [{"nameIdentifier": "5225", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Youichi"}], "nameIdentifiers": [{"nameIdentifier": "5226", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Tetsurou"}], "nameIdentifiers": [{"nameIdentifier": "5227", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yajima, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "5228", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uehara, Ryouhei"}], "nameIdentifiers": [{"nameIdentifier": "5229", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hino, Naoyuki"}], "nameIdentifiers": [{"nameIdentifier": "5230", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Narita, Syouhei"}], "nameIdentifiers": [{"nameIdentifier": "5231", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Hisaya"}], "nameIdentifiers": [{"nameIdentifier": "5232", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Seina"}], "nameIdentifiers": [{"nameIdentifier": "5233", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "5234", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "HepRes48_E232.pdf", "filesize": [{"value": "232.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 232700.0, "url": {"label": "HepRes48_E232.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1088/files/HepRes48_E232.pdf"}, "version_id": "2f73da1e-bc17-4e8b-81dc-a526a65e4570"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "direct-acting antivirals", "subitem_subject_scheme": "Other"}, {"subitem_subject": "hepatitis C virus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "patient-reported outcomes", "subitem_subject_scheme": "Other"}, {"subitem_subject": "quality of life, symptoms", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/38333", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-03-01"}, "publish_date": "2019-03-01", "publish_status": "0", "recid": "1088", "relation": {}, "relation_version_is_last": true, "title": ["Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals"], "weko_shared_id": -1}
Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals
http://hdl.handle.net/10069/38333
http://hdl.handle.net/10069/38333126c1f30-72f0-44a2-a27c-f8e079eec7f7
名前 / ファイル | ライセンス | アクション |
---|---|---|
HepRes48_E232.pdf (232.7 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-03-01 | |||||
タイトル | ||||||
タイトル | Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | direct-acting antivirals | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | hepatitis C virus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | patient-reported outcomes | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | quality of life, symptoms | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ichikawa, Tatsuki
× Ichikawa, Tatsuki× Miyaaki, Hisamitsu× Miuma, Satoshi× Taura, Naota× Motoyoshi, Yasuhide× Akahoshi, Hiroshi× Nakamura, Satomi× Nakamura, Junpei× Takahashi, Youichi× Honda, Tetsurou× Yajima, Hiroyuki× Uehara, Ryouhei× Hino, Naoyuki× Narita, Syouhei× Tanaka, Hisaya× Sasaki, Seina× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Aim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs. Methods: A total of 107 patients with chronic HCV infection were treated with DAAs. Daclatasvir/asunaprevir or sofosbuvir/ledipasvir was used for HCV 1B infection, and sofosbuvir/ribavirin for HCV 2A/2B infection. The PROs measured at the start of treatment and 1 year after the start of treatment were cirrhosis-related symptom score (CSS), presence of restless legs syndrome (RLS), Epworth sleepiness scale (ESS), Pittsburg sleep quality index (PSQI), Kessler 6 score (K-6), and the SF-36 to measure quality of life (QOL). All patients had a sustained virologic response rate of 24. Results: The CSS, PSQI, K-6, and RLS scores were improved 1 year after beginning treatment. However, QOL had not recovered. Changes in total CSS were correlated with HCV genotype, sex, hypertensive drug use, serum low-density lipoprotein, and ESS at the start of treatment and RLS 1 year after the start of treatment. The factors that contributed to worsening of CSS were HCV genotype 2B and RLS 1 year after the start of treatment. Conclusion: Treatment with DAAs eliminated HCV-RNA and improved most symptoms, but QOL did not recover. | |||||
書誌情報 |
Hepatology Research 巻 48, 号 3, p. E232-E239, 発行日 2018-02 |
|||||
出版者 | ||||||
出版者 | 日本肝臓学会 | |||||
出版者別言語 | ||||||
The Japan Society of Hepatology | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 13866346 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/hepr.12974 | |||||
権利 | ||||||
権利情報 | c 2017 The Japan Society of Hepatology. This is the peer reviewed version of the following article: Hepatology Research, 48(3), pp.E232-E239; 2018, which has been published in final form at http://dx.doi.org/10.1111/hepr.12974. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Hepatology Research, 48(3), pp.E232-E239; 2018 |